

**Table S1.**

Percentage mean difference from baseline assessment (% $\Delta$   $\pm$  Standard Error) of renal function, pulmonary function and immunosuppressive dosage in all transplanted patients (n = 26)

	Baseline-1st Month	Baseline-3rd Month	Baseline-6th Month	Baseline-12th Month	<i>P</i>
% $\Delta$ Creatinine	-15.2 $\pm$ 17.5	-17.3 $\pm$ 21.1	-19.1 $\pm$ 22	-17.3 $\pm$ 21	0.932
% $\Delta$ eGFR	23.5 $\pm$ 37.2	30.1 $\pm$ 46.8	35.8 $\pm$ 48.1	24.0 $\pm$ 55.6	0.789
% $\Delta$ FEV <sub>1</sub>	4.5 $\pm$ 2.8	-1.2 $\pm$ 4.1	-0.1 $\pm$ 5.7	0.5 $\pm$ 7.2	0.832
% $\Delta$ FVC	4.6 $\pm$ 2.0	1.1 $\pm$ 2.9	0.07 $\pm$ 3.9	0.2 $\pm$ 3.3	0.687
% $\Delta$ ISD	-37.7 $\pm$ 5.5	-41.8 $\pm$ 5.8	-34.7 $\pm$ 6.1	-49.9 $\pm$ 6.7	0.375

EGFR, estimated glomerular filtration rate; FEV<sub>1</sub>, forced expiratory volume in 1st second; FVC, forced vital capacity; ISD, immunosuppressive dosage.

**Table S2.**

Percentage mean difference from baseline assessment ( $\% \Delta \pm$  Standard Error) of pulmonary function in CLAD (n = 17) and non-CLAD (n = 9) patients.

	<b>Group</b>	<b>Baseline-1st month</b>	<b>Baseline-3rd month</b>	<b>Baseline-6th month</b>	<b>Baseline-12th month</b>	<b><i>P</i></b>
<b><math>\% \Delta</math> FEV<sub>1</sub></b>	CLAD	5.8 ± 4.1	-5.0 ± 5.6	-7.5 ± 6.8	-10.8 ± 9.7	0.281
	Non-CLAD	2.2 ± 3.0	5.8 ± 5.2	11.2 ± 9.3	14.8 ± 9.1	0.613
	<i>P</i> difference	0.561	0.219	0.109	0.078	
<b><math>\% \Delta</math> FVC</b>	CLAD	4.8 ± 2.9	0.4 ± 4.3	-4.5 ± 5.5	-5.7 ± 4.7	0.337
	Non-CLAD	4.4 ± 2.5	2.5 ± 2.7	7.2 ± 4.5	7.7 ± 3.3	0.529
	<i>P</i> difference	0.929	0.736	0.151	0.043	

CLAD, chronic lung allograft dysfunction; FEV<sub>1</sub>, forced expiratory volume in 1st second; FVC, forced vital capacity.

**Table S3.**

Percentage mean difference from baseline assessment ( $\% \Delta \pm$  Standard Error) of pulmonary function in RAS (n = 7) and BOS (n = 10) patients.

	<b>Group</b>	<b>Baseline-1st month</b>	<b>Baseline-3rd month</b>	<b>Baseline-6th month</b>	<b>Baseline-12th month</b>	<b><i>P</i></b>
<b><math>\% \Delta</math> FEV<sub>1</sub></b>	BOS	8.0 $\pm$ 4.8	1.6 $\pm$ 6.0	4.4 $\pm$ 6.8	-0.8 $\pm$ 11.6	0.839
	RAS	2.9 $\pm$ 7.5	-14.6 $\pm$ 9.9	-23.5 $\pm$ 10.2	-25.8 $\pm$ 15.9	0.214
	<i>P</i> difference	0.558	0.159	0.034	0.229	
<b><math>\% \Delta</math> FVC</b>	BOS	6.9 $\pm$ 5.1	6.6 $\pm$ 6.2	4.6 $\pm$ 6.7	-3.4 $\pm$ 7.0	0.691
	RAS	2.2 $\pm$ 1.7	-8.4 $\pm$ 4.1	-16.6 $\pm$ 7.1	-9.2 $\pm$ 6.5	0.071
	<i>P</i> difference	0.454	0.088	0.053	0.584	

BOS, bronchiolitis obliterans syndrome; FEV<sub>1</sub>, forced expiratory volume in 1st second; FVC, forced vital capacity; RAS, restrictive allograft syndrome.

**Table S4.**

Percentage mean difference from baseline assessment ( $\% \Delta \pm$  Standard Error) of pulmonary function and immunosuppressive dosage in RAS (n = 7), BOS (n = 10) and non-CLAD (n = 9) patients.

	<b>Group</b>	<b>Baseline-1st month</b>	<b>Baseline-3rd month</b>	<b>Baseline-6th month</b>	<b>Baseline-12th month</b>
<b><math>\% \Delta</math> FEV<sub>1</sub></b>	RAS	2.9 $\pm$ 7.5	-14.6 $\pm$ 9.9	-23.5 $\pm$ 10.2	-25.8 $\pm$ 15.9
	BOS	8.0 $\pm$ 4.8	1.6 $\pm$ 6.0	4.4 $\pm$ 6.8	-0.8 $\pm$ 11.6
	Non-CLAD	2.2 $\pm$ 3.0	5.8 $\pm$ 5.2	11.2 $\pm$ 9.3	14.8 $\pm$ 9.1
	<i>P</i> difference	0.666	0.137	0.037	0.091
<b><math>\% \Delta</math> FVC</b>	RAS	2.2 $\pm$ 1.7	-8.4 $\pm$ 4.1	-16.6 $\pm$ 7.1	-9.2 $\pm$ 6.5
	BOS	6.9 $\pm$ 5.1	6.6 $\pm$ 6.2	4.6 $\pm$ 6.7	-3.4 $\pm$ 7.0
	Non-CLAD	4.4 $\pm$ 2.5	2.5 $\pm$ 2.7	7.2 $\pm$ 4.5	7.7 $\pm$ 3.3
	<i>P</i> difference	0.685	0.121	0.031	0.112
<b><math>\% \Delta</math> ISD</b>	BOS	-26.0 $\pm$ 10.7	-37.2 $\pm$ 9.7	-25.9 $\pm$ 11.9	-45.0 $\pm$ 8.2
	RAS	-47.1 $\pm$ 5.9	-34.2 $\pm$ 13.4	-31.3 $\pm$ 8.4	-53.3 $\pm$ 9.9
	Non-CLAD	-43.3 $\pm$ 9.2	-52.9 $\pm$ 7.7	-45.2 $\pm$ 9.1	-51.6 $\pm$ 12.9
	<i>P</i> difference	0.254	0.395	0.388	0.893

BOS, bronchiolitis obliterans syndrome; CLAD, chronic lung allograft dysfunction; FEV<sub>1</sub>, forced expiratory volume in 1st second; FVC, forced vital capacity; ISD, immunosuppressive dosage; RAS, restrictive allograft syndrome.

**Table S5.**

Means ( $\pm$  Standard Error) of pulmonary function in non-CLAD (n = 9) versus RAS (n = 7) and BOS (n = 10) patients separately.

	<b>Group</b>	<b>Baseline</b>	<b>1 Month</b>	<b>3 Month</b>	<b>6 Month</b>	<b>12 Month</b>
<b>FEV<sub>1</sub></b>	BOS	46.7 $\pm$ 6.2	49.5 $\pm$ 6.9	47.1 $\pm$ 6.8	48.5 $\pm$ 8.8	51.0 $\pm$ 9.7
	Non-CLAD	74.8 $\pm$ 7.1	76.1 $\pm$ 7.3	78.0 $\pm$ 7.3	80.3 $\pm$ 6.9	77.8 $\pm$ 5.2
	<i>P</i> difference	0.008	0.002	0.0003	0.0006	0.009
<b>FVC</b>	BOS	77.6 $\pm$ 4.6	80.4 $\pm$ 5.6	82.3 $\pm$ 5.9	79.1 $\pm$ 8.3	81.0 $\pm$ 5.5
	Non-CLAD	81.8 $\pm$ 4.7	85.4 $\pm$ 5.2	83.6 $\pm$ 4.8	87.5 $\pm$ 5.6	84.1 $\pm$ 3.9
	<i>P</i> difference	0.283	0.082	0.534	0.167	0.015
<b>FEV<sub>1</sub></b>	RAS	59.2 $\pm$ 2.0	60.2 $\pm$ 2.7	50.0 $\pm$ 5.2	44.8 $\pm$ 6.3	44.2 $\pm$ 9.6
	Non-CLAD	74.8 $\pm$ 7.1	76.1 $\pm$ 7.3	78.0 $\pm$ 7.36	80.3 $\pm$ 6.9	77.8 $\pm$ 5.25
	<i>P</i> difference	0.176	0.166	0.042	0.027	0.056
<b>FVC</b>	RAS	70.0 $\pm$ 5.7	71.8 $\pm$ 6.9	63.4 $\pm$ 4.2	53.1 $\pm$ 3.2	56.5 $\pm$ 2.9
	Non-CLAD	81.8 $\pm$ 4.7	85.4 $\pm$ 5.2	83.6 $\pm$ 4.8	87.5 $\pm$ 5.6	84.1 $\pm$ 3.9
	<i>P</i> difference	0.217	0.161	0.024	0.013	0.020

BOS, bronchiolitis obliterans syndrome; CLAD, chronic lung allograft dysfunction; FEV<sub>1</sub>, forced expiratory volume in 1st second; FVC, forced vital capacity; RAS, restrictive allograft syndrome.